Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.

The Journal of investigative dermatology - 1 Nov 2017

Ishida Yoshihiro, Otsuka Atsushi, Tanaka Hidenori, Levesque Mitchell P, Dummer Reinhard, Kabashima Kenji

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to HLA-A Antigens
Share to Japan
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Nivolumab

Share to Skin Neoplasms

Share to Survival Analysis

Source

Identifiers

PMID: 28736235
DOI: 10.1016/j.jid.2017.06.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.PMID 28736235Read ↗

Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical CharacteristicsSemantic proximity Read ↗

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaSemantic proximity Read ↗

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanomaSemantic proximity Read ↗

Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.Semantic proximity Read ↗

Putative linkage between HLA class I polymorphism and the susceptibility to malignant melanoma.Semantic proximity Read ↗

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.Semantic proximity Read ↗

Genetic inference of immune responsiveness of melanoma cancer patients to TIL therapySemantic proximity Read ↗

Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood.Semantic proximity Read ↗

Role of altered expression of HLA class I molecules in cancer progression.Semantic proximity Read ↗

Association Between Genetic Variants and the Risk of Nivolumab-Induced Immune-Related Adverse EventsSemantic proximity Read ↗

Synergy of HLA class I and II shapes the timing of antitumor immune responseSemantic proximity Read ↗

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.